Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.39 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 3/20 | 0.36 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815939 | 0.98 | SLC15A2 (0.39) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL5792595 | 0.91 | SLC15A2 (0.44) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL5598772 | 0.90 | ERAP2 (0.48) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL5598767 | 0.90 | ERAP2 (0.48) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL4588260 | 0.90 | SLC15A2 (0.42) | SLC15A2ERAP2ERAP1LNPEPGHSR | |
| SCHEMBL2815934 | 0.90 | ERAP2 (0.47) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL4587311 | 0.90 | ERAP2 (0.47) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL4588807 | 0.89 | SLC15A2 (0.41) | SLC15A2OPRK1GHSR | |
| SCHEMBL30906004 | 0.89 | ERAP2 (0.44) | SLC15A2OPRK1ERAP2ERAP1LNPEP | |
| SCHEMBL29937046 | 0.89 | ERAP2 (0.47) | SLC15A2OPRK1ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | SLC15A2 2656/4885OPRK1 4363/4885ERAP2 576/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | SLC15A2 1582/4885OPRK1 2506/4885ERAP2 1179/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | SLC15A2 2656/4885OPRK1 4363/4885ERAP2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.